Sam Brusco, Associate Editor06.01.22
Medtronic’s Microstream capnography (CO2) and INVOS regional oximetry (rSO2) continuous monitoring solutions can now be integrated with GE Healthcare’s Carescape precision monitoring platform thanks to recent U.S. Food and Drug Administration (FDA) clearance and CE mark approval.
The combined tool also features GE Healthcare’s FlexAcuity to choose care options based on patient acuity needs and assist in earlier detection of patient deterioration.
“Our longstanding collaboration with Medtronic allows GE Healthcare to integrate clinically advanced parameters to enable clinicians with precision monitoring for individualized care,” Neal Sandy, GM for Monitoring Solutions at GE Healthcare told the press. “We are able to add these capabilities to both new and existing enterprise monitoring systems, ensuring clinicians have access to real-time, reliable patient insights that can play a critical role in care decisions and outcomes.”
INVOS rSO2 monitors for signs of hemodynamic changes and deteriorating conditions associated with cerebral desaturation events. According to clinical studies, INVOS tech can help clinicians return the patient’s rSO2 to baseline and improve hospital length of stay among other post-op outcomes.
Microstream CO2 tech uses a proprietary CO2-specific infrared wavelength that is unaffected by presence of other gases to help indicate patient decline earlier. Algorithms were designed to boost patient safety, improve clinical workflow, and ease alarm fatigue by cutting clinically insignificant nuisance alarms in half.
“Medtronic and GE Healthcare are both committed to expanding access to patient care around the world,” said Frank Chan, president of Medtronic’s Patient Monitoring business. “This collaboration brings together our combined medical technology leadership to improve workflow, allowing clinicians more time to focus on what matters most—the patient. Together, we are empowering clinicians with actionable insights to personalize care.”
The combined tool also features GE Healthcare’s FlexAcuity to choose care options based on patient acuity needs and assist in earlier detection of patient deterioration.
“Our longstanding collaboration with Medtronic allows GE Healthcare to integrate clinically advanced parameters to enable clinicians with precision monitoring for individualized care,” Neal Sandy, GM for Monitoring Solutions at GE Healthcare told the press. “We are able to add these capabilities to both new and existing enterprise monitoring systems, ensuring clinicians have access to real-time, reliable patient insights that can play a critical role in care decisions and outcomes.”
INVOS rSO2 monitors for signs of hemodynamic changes and deteriorating conditions associated with cerebral desaturation events. According to clinical studies, INVOS tech can help clinicians return the patient’s rSO2 to baseline and improve hospital length of stay among other post-op outcomes.
Microstream CO2 tech uses a proprietary CO2-specific infrared wavelength that is unaffected by presence of other gases to help indicate patient decline earlier. Algorithms were designed to boost patient safety, improve clinical workflow, and ease alarm fatigue by cutting clinically insignificant nuisance alarms in half.
“Medtronic and GE Healthcare are both committed to expanding access to patient care around the world,” said Frank Chan, president of Medtronic’s Patient Monitoring business. “This collaboration brings together our combined medical technology leadership to improve workflow, allowing clinicians more time to focus on what matters most—the patient. Together, we are empowering clinicians with actionable insights to personalize care.”